The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress).
 
Lindsey Elizabeth Roeker
Stock and Other Ownership Interests - Abbott Laboratories (I); Abbvie (I)
Honoraria - Aptitude Health; OncLive/MJH Life Sciences; Pfizer; Vaniam Group
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Janssen; Loxo/Lilly; Pharmacyclics; Pharmacyclics; TG Therapeutics
Research Funding - Aptose Biosciences (Inst); Loxo/Lilly (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Loxo/Lilly; Vaniam Group
 
Alvaro Jose Alencar
Consulting or Advisory Role - Amgen; BeiGene; Epizyme; Incyte; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Seagen
Research Funding - Loxo
 
Guru Subramanian Guru Murthy
Honoraria - Cardinal Health; Gilead Sciences; TG therapeutics
Consulting or Advisory Role - Cancer Expert Now; Market Plus; Putnam Associates; Qessential Medical Marketing Research; SmartAnalyst; techspert.io
Research Funding - Xencor
 
Marc Steven Hoffmann
Honoraria - AstraZeneca; Janssen; Kite, a Gilead Company; Novartis; Pharmacyclics; TG Therapeutics
Consulting or Advisory Role - AstraZeneca; Janssen; Kite, a Gilead Company; Novartis; Pharmacyclics; TG Therapeutics
 
John M. Pagel
Employment - Loxo
Leadership - Loxo
Stock and Other Ownership Interests - Loxo
Consulting or Advisory Role - Actinium Pharmaceuticals; AstraZeneca; BeiGene; Epizyme; Gilead Sciences; Loxo; MEI Pharma; MorphoSys; TG Therapeutics
 
Vishalkumar Patel
Employment - Loxo/Lilly
Stock and Other Ownership Interests - Lilly
 
James Michael Pauff
Employment - Abbvie; Loxo/Lilly
Stock and Other Ownership Interests - Abbvie; Lilly
Travel, Accommodations, Expenses - Abbvie; Loxo/Lilly
 
Pier Luigi Zinzani
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb; Celltrion; EUSA Pharma; Gilead Sciences; Incyte; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Novartis; Roche; Sandoz; Secura BIO; SERVIER; Takeda; TG Therapeutics
Speakers' Bureau - EUSA Pharma; MSD; Novartis
 
Steven Le Gouill
No Relationships to Disclose
 
Anthony Mato
Consulting or Advisory Role - Abbvie/Genentech; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; Bristol-Myers Squibb/Pfizer; Celgene; Curio/Vaniam Group; DTRM; Johnson & Johnson; Loxo/Lilly; Merck; Pharmacyclics; TG Therapeutics; Verastem
Research Funding - Abbvie/Genentech; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; DTRM; Genmab; Johnson & Johnson; LOXO; Nurix; Pharmacyclics; Regeneron; Sunesis Pharmaceuticals; TG Therapeutics
 
Wojciech Jurczak
Consulting or Advisory Role - AstraZeneca; Debiopharm Group; Epizyme; Janssen-Cilag; Roche
Research Funding - Acerta Pharma; Bayer; BeiGene; Debiopharm Group; Epizyme; Incyte; Janssen-Cilag; MEI Pharma; Morphosys; Roche; Sandoz-Novartis; Takeda; TG Therapeutics; TG Therapeutics